CYPL: OTCBB, Frankfurt Exchange WKN:XYIA

EDMONTON, Jan. 18 /CNW/ - Cyplasin Biomedical Ltd. (CBL), is pleased to announce the commencement of a second animal efficacy study of its lead product Cyplasin-SC(TM) for use as a melanoma cancer therapeutic. The second study will be performed by Aurigon Life Sciences GmbH (Tutzing, Germany) to reconfirm CBL's previously successful animal efficacy study of Cyplasin-SC for melanoma and to test a newly formulated Cyplasin-solution that will be even better tolerated by the mouse organism.

The second study of Cyplasin-SC will be performed as before where mice with a suppressed immune system are given human melanoma cells in order to create melanoma tumours in the mice. These melanoma tumours will then be allowed to grow to a sufficient size to allow for repeated microinjection of Cyplasin-SC at or near the tumour site. After a specified period of time the tumours will then be analysed to determine if the Cyplasin-SC has retarded or stopped the growth of the tumour.

"Our first study confirmed a definitive correlation with the amount of Cyplasin-SC being given versus a reduced tumour size and we have every confidence this second study will be as successful," stated Professor Petzelt, CSO of the Company. He further stated "once we have obtained and analysed the new confirming data we can then plan on how to best move into the animal toxicology testing phase before IND submission and the resultant initiation of phase I, experiments involving humans."

Cyplasin-SC is being developed for use as an anticancer therapeutic drug for melanoma and skin cancer.

About Melanoma

Around 160,000 new cases of new melanoma cases are diagnosed worldwide each year. Melanoma is more frequently found in Caucasian males and is more common in Caucasian populations living in sunny climates than in other groups. Market statistics for skin cancer and melanoma show that melanoma currently affects more then 2.4 million people worldwide with 62,000 new cases being reported in the USA every year. Australia has the highest rate of melanoma in the world among males and has the second highest rate in the world among females (Australia's Health 2004, AIHW). According to the WHO Report the world wide incidence has doubled over the past 20 years with about 48,000 melanoma related deaths occurring worldwide per annum.

About Cyplasin-SC(TM)

Cyplasin-SC(TM) has demonstrated a selective ability to rapidly kill certain types of cancer cells while leaving normal non-cancerous cells untouched. Cyplasin-SC is a protein originally discovered and isolated by Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The protein can now be manufactured as a recombinant protein which allows the company to develop the protein as an anti-cancer therapeutic product. Patents have been issued to the Company covering the Cyplasin-SC protein.

About Cyplasin Biomedical Ltd. (CBL)

Founded in 2007 and headquartered in Edmonton, Canada with a research laboratory close to Berlin, Germany, CBL is dedicated to bringing new anticancer therapeutics to the marketplace. The Company's current goal is to develop and commercialize the anticancer properties of Cyplasin-SC(TM) against skin cancer and melanoma. CBL is publicly traded (CYPL: OTCBB).

Forward-Looking Statements

This Press release includes and is based, inter alia, on forward-looking information and statements that are subject to risks and uncertainties that could cause actual results to differ. Such forward-looking information and statements are based without limitation, as statements regarding future drug development activities, anticipated products, or anticipated future revenues, benefits or advantages, and the future plans and objectives of the Company, that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, such as market acceptance of new products and services, changes in governmental regulations, interest rates, fluctuations in currency exchange rates and such other factors as may be discussed from time to time that may cause actual results or performance to differ materially from those currently anticipated in such statements. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "believes", "estimates" or similar expressions. Although Cyplasin Biomedical Ltd., believes that its expectations and the information in this Press release were based upon reasonable assumptions at the time when they were made, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in this Press release. Cyplasin Biomedical Ltd., makes no representation or warranty, expressed or implied, as to the accuracy, reliability or completeness of the information in the Press release, and neither Cyplasin Biomedical nor any of their directors, officers or employees will have any liability to you or any other persons resulting from your use of the information in the Press release. The OTCBB Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.

For further information

Garth Likes, President & CEO, Cyplasin Biomedical Ltd., www.cyplasin.com, Tel 001-780-469-2975, Fax 001-780-699-7933, glikes@cyplasin.com
Professor Christian Petzelt (CSO), Cyplasin Biomedical Ltd., www.cyplasin.com, Tel 0049-30-95992761, cpetzelt@cyplasin.com